ABS-201 in Androgenetic Alopecia
Absci
ABS-201 is an anti-PRLR antibody in AGA; this market requires numerical TAHC improvement, not safety/PK alone, by Dec.
Current Markets
Sonelokimab in Psoriatic Arthritis
MoonLake Immunotherapeutics
Sonelokimab is being tested in biologic-naive psoriatic arthritis; this market resolves on Week 16 ACR50 success by Sept.
GPS Maintenance Therapy in AML Remission
SELLAS Life Sciences Group
GPS is being tested as AML maintenance therapy; this market resolves on statistically significant overall survival success by Nov.
Upcoming Trials
#1
NCT04850118Sign in to save notifications for this NCT.
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPX-Linked Retinitis PigmentosaBeacon TherapeuticsPhase 2 / Phase 3Jun 30, 2026
- Status
- Active Not Recruiting
- Intervention
- rAAV2tYF-GRK1-hRPGRco; Control
- Primary completion
- Jun 30, 2026
- Suggestions
- 1
- This week
- +1
- All time
- +8
- First suggested
- Apr 22, 2026
- Latest suggestion
- Apr 22, 2026
#2
NCT05733546Sign in to save notifications for this NCT.
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderMajor Depressive DisorderCOMPASS Pathways (CMPS)Phase 2Sep 2025
- Status
- Active Not Recruiting
- Intervention
- Psilocybin
- Primary completion
- Sep 2025
- Suggestions
- 1
- This week
- +1
- All time
- +7
- First suggested
- Apr 13, 2026
- Latest suggestion
- Apr 13, 2026
#3
NCT06347159Sign in to save notifications for this NCT.
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)Hypertrophic CardiomyopathyEdgewise Therapeutics, Inc. (EWTX)Phase 2Jun 2026
- Status
- Active Not Recruiting
- Intervention
- EDG-7500
- Primary completion
- Jun 2026
- Suggestions
- 1
- This week
- 0
- All time
- +2
- First suggested
- Apr 13, 2026
- Latest suggestion
- Apr 13, 2026
#4
NCT06109649Sign in to save notifications for this NCT.
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With VitiligoVitiligoClinuvel, Inc.Phase 3Dec 2025
- Status
- Active Not Recruiting
- Intervention
- Afamelanotide and NB-UVB Light; NB-UVB Light
- Primary completion
- Dec 2025
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- May 23, 2026
- Latest suggestion
- May 23, 2026
#5
NCT04280705Sign in to save notifications for this NCT.
Adaptive COVID-19 Treatment Trial (ACTT)COVID-19National Institute of Allergy and Infectious Diseases (NIAID)Phase 3May 21, 2020
- Status
- Completed
- Intervention
- Placebo; Remdesivir
- Primary completion
- May 21, 2020
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 20, 2026
- Latest suggestion
- Apr 20, 2026
#6
NCT06344104Sign in to save notifications for this NCT.
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionUncontrolled Hypertension; Resistant HypertensionAstraZeneca (AZN)Phase 3Nov 24, 2025
- Status
- Completed
- Intervention
- Baxdrostat; Placebo
- Primary completion
- Nov 24, 2025
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 14, 2026
- Latest suggestion
- Apr 14, 2026
#7
NCT06389877Sign in to save notifications for this NCT.
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)Alpha 1-Antitrypsin DeficiencyBeam Therapeutics Inc. (BEAM)Phase 1 / Phase 2May 2028
- Status
- Recruiting
- Intervention
- BEAM-302
- Primary completion
- May 2028
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 13, 2026
- Latest suggestion
- Apr 13, 2026
#8
NCT07420283Sign in to save notifications for this NCT.
A Study of Brenipatide in Participants With Opioid Use DisorderOpioid Use DisorderEli Lilly and Company (LLY)Phase 2Mar 2028
- Status
- Recruiting
- Intervention
- Brenipatide; Placebo; Buprenorphine
- Primary completion
- Mar 2028
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 12, 2026
- Latest suggestion
- Apr 12, 2026
#9
NCT07219953Sign in to save notifications for this NCT.
A Study of Brenipatide in Participants With Alcohol Use DisorderAlcohol Use DisorderEli Lilly and Company (LLY)Phase 3Apr 2028
- Status
- Recruiting
- Intervention
- LY3537031; Placebo
- Primary completion
- Apr 2028
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 12, 2026
- Latest suggestion
- Apr 12, 2026
#10
NCT06634420Sign in to save notifications for this NCT.
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)Hereditary AngioedemaIntellia Therapeutics (NTLA)Phase 3Feb 10, 2026
- Status
- Active Not Recruiting
- Intervention
- NTLA-2002; Normal Saline IV Administration
- Primary completion
- Feb 10, 2026
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 12, 2026
- Latest suggestion
- Apr 12, 2026
#11
NCT05933577Sign in to save notifications for this NCT.
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)MelanomaMerck Sharp & Dohme LLC (MRK)Phase 3Oct 26, 2029
- Status
- Active Not Recruiting
- Intervention
- Intismeran autogene; Pembrolizumab; Placebo
- Primary completion
- Oct 26, 2029
- Suggestions
- 1
- This week
- 0
- All time
- 0
- First suggested
- Apr 12, 2026
- Latest suggestion
- Apr 12, 2026